Jasper Therapeutics Stock Investor Sentiment
| JSPR Stock | USD 2.28 0.10 4.59% |
Slightly above 52% of Jasper Therapeutics' retail investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Jasper Therapeutics suggests that some traders are interested. Jasper Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Jasper Therapeutics. Many technical investors use Jasper Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Comfort Level 52
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Jasper Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Jasper Therapeutics.
News SentimentNeutral | Hype SentimentBullish | Insider SentimentWaiting |
Jasper Historical Sentiment
Although Jasper Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Jasper, such as negative comments on social media and news outlets, may cause fear in the market and push Jasper Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Jasper.
Jasper Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Jasper Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Jasper Therapeutics Historical Investor Sentiment
Investor biases related to Jasper Therapeutics' public news can be used to forecast risks associated with an investment in Jasper. The trend in average sentiment can be used to explain how an investor holding Jasper can time the market purely based on public headlines and social activities around Jasper Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Jasper Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Jasper Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Jasper Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Jasper Therapeutics.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of Jasper Therapeutics' Stock prices. Below is the latest headlines and news related to Jasper Therapeutics Stock. The global stock market is bearish. About 67% of major world exchanges and indexes are down. See today's market update for more information.
There is far too much social signal, news, headlines, and media speculation about Jasper Therapeutics that are available to investors today. This information is accessible both publicly - through Jasper Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Jasper-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Jasper Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jasper Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jasper Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jasper Therapeutics alpha.
Jasper Largest EPS Surprises
Earnings surprises can significantly impact Jasper Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-08-09 | 2024-06-30 | -1.09 | -0.97 | 0.12 | 11 | ||
2024-11-07 | 2024-09-30 | -1.07 | -1.24 | -0.17 | 15 | ||
2024-05-14 | 2024-03-31 | -1.23 | -1.03 | 0.2 | 16 | ||
2022-05-12 | 2022-03-31 | -0.35 | -0.06 | 0.29 | 82 | ||
2025-03-03 | 2024-12-31 | -1.2278 | -1.62 | -0.3922 | 31 | ||
2021-11-12 | 2021-09-30 | -0.28 | -0.69 | -0.41 | 146 |
There is far too much social signal, news, headlines, and media speculation about Jasper Therapeutics that are available to investors today. This information is accessible both publicly - through Jasper Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of Jasper-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of Jasper Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jasper Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jasper Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jasper Therapeutics alpha.
Jasper Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Gainey McKenna Egleston Announces A ClassAction Lawsuit Has Been Filed Against Jasper Therapeutics, Inc. | 09/22/2025 |
2 | JSPR INVESTOR ALERT Bronstein, Gewirtz Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Ac... | 09/29/2025 |
3 | ROSEN, GLOBAL INVESTOR RIGHTS COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action JSP... | 10/10/2025 |
4 | DEADLINE ALERT for NX, JSPR, KBR, RICK Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions | 10/17/2025 |
5 | ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action JSPR | 10/20/2025 |
6 | DEADLINE ALERT for CYTK, NX, JSPR, and KBR The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders | 10/22/2025 |
7 | ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action... | 10/23/2025 |
8 | Jasper Therapeutics, Inc. Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit | 10/29/2025 |
9 | JSPR DEADLINE ROSEN, SKILLED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors with Losses in Excess of 100K to Secure Counsel Before Important D... | 10/31/2025 |
Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.